Amber E. De Groot
About Amber E. De Groot
Amber E. De Groot is a scientist specializing in translational science, with a focus on developing pharmacodynamic assays for cancer therapies. She holds a Ph.D. in Pharmacology and Molecular Sciences from The Johns Hopkins University and currently works at Arcus Biosciences in Hayward, California.
Work at Arcus Biosciences
Amber E. De Groot has been employed at Arcus Biosciences as a Scientist in Translational Science since 2020. In this role, she develops pharmacodynamic assays to monitor the effects of cancer therapies within clinical trial settings. Her work is centered on translational research that seeks to improve patient health outcomes through innovative cancer treatment strategies. Located in Hayward, California, Arcus Biosciences focuses on creating therapies that target the tumor microenvironment and enhance the effectiveness of immunotherapy.
Education and Expertise
Amber E. De Groot earned her Doctor of Philosophy (Ph.D.) in Pharmacology and Molecular Sciences from The Johns Hopkins University School of Medicine, completing her studies from 2015 to 2020. Prior to this, she obtained a Bachelor of Arts (BA) in Biochemistry and Molecular Biology from UC Berkeley, where she studied from 2011 to 2015. Her educational background provides her with a strong foundation in the biological sciences, particularly in the context of cancer research and therapy development.
Background
Amber E. De Groot began her academic journey at UC Berkeley, where she studied Biochemistry and Molecular Biology. After completing her undergraduate degree, she pursued a Ph.D. at The Johns Hopkins University School of Medicine. During her doctoral studies, she worked as a Ph.D. Candidate from 2015 to 2020. Additionally, she gained practical experience as a Graduate Research Intern at NextCure, Inc. for three months in 2020, where she further developed her research skills in a professional setting.
Research Focus
Amber E. De Groot's research is primarily focused on the development of therapies that specifically target the tumor microenvironment. She aims to enhance the effectiveness of immunotherapy through her work in translational research. By developing pharmacodynamic assays, she monitors the impacts of cancer therapies, contributing to the advancement of novel treatment strategies that aim to improve patient health outcomes.